Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T Cells-mediated Immune Response

Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Use of music to enhance sleep and psychological outcomes in critically ill patients: a protocol for a systematic review and meta-analysis.

BMJ open·2021

Same author

Further Characterization of Glycoform-Selective Prions of Variably Protease-Sensitive Prionopathy.

Pathogens (Basel, Switzerland)·2021

Same author

Separation and anti-inflammatory evaluation of phytochemical constituents from Pleurospermum candollei (Apiaceae) by high-speed countercurrent chromatography with continuous sample load.

Journal of separation science·2021

Same author

Juglone regulates gut microbiota and Th17/Treg balance in DSS-induced ulcerative colitis.

International immunopharmacology·2021

Same author

Argonaute integrated single-tube PCR system enables supersensitive detection of rare mutations.

Nucleic acids research·2021

Same author

Overexpression of ATP-binding cassette transporters associated with sulfoxaflor resistance in Aphis gossypii glover.

Pest management science·2021

Search research articles

Related Experiment Video

Updated: Jun 1, 2026

Murine Mesenteric Lymphadenectomy for Selective Disruption of Lymphatic Communication with Region-Specific Gut

Murine Mesenteric Lymphadenectomy for Selective Disruption of Lymphatic Communication with Region-Specific Gut

Published on: December 30, 2025

Rewiring the immune circuit: programming tumor-draining lymph node immunity with nanotechnology.

Xu Chen¹, Meiyan Zou¹, Nina Li¹

¹Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China.

Journal of Nanobiotechnology

|May 30, 2026

Summary

Tumor-draining lymph nodes (TDLNs) are key immunotherapy sites. Nanotechnology can reprogram TDLNs to enhance anti-tumor immunity by controlling immune responses within these critical immune niches.

Keywords:

Antigen presentation Nanoparticles Sentinel lymph nodes T cell Tumor immunotherapy Tumor-draining lymph nodes

More Related Videos

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8⁺ T Cells During Tumorigenesis

Published on: January 26, 2024

Intra-lymph Node Injection of Biodegradable Polymer Particles

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Related Experiment Videos

Last Updated: Jun 1, 2026

Murine Mesenteric Lymphadenectomy for Selective Disruption of Lymphatic Communication with Region-Specific Gut

Murine Mesenteric Lymphadenectomy for Selective Disruption of Lymphatic Communication with Region-Specific Gut

Published on: December 30, 2025

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8+ T Cells During Tumorigenesis

Draining Lymph Node Metastasis Model for Assessing the Dynamics of Antigen-Specific CD8⁺ T Cells During Tumorigenesis

Published on: January 26, 2024

Intra-lymph Node Injection of Biodegradable Polymer Particles

Intra-lymph Node Injection of Biodegradable Polymer Particles

Published on: January 2, 2014

Area of Science:

Immunology
Nanotechnology
Cancer Research

Background:

Tumor-draining lymph nodes (TDLNs) are crucial for cancer immunotherapy, acting as sites for metastasis and antigen presentation.
They exhibit a dual role, supporting both immune activation and suppression, yet are often viewed primarily as metastatic risks.
Current strategies often overlook the potential for therapeutic reprogramming of TDLNs as immune niches.

Purpose of the Study:

To review nanotechnology-enabled strategies for modulating immune function within TDLNs.
To articulate principles governing lymphatic access, intranodal localization, and immune engagement for nanomedicine.
To identify challenges and provide guidance for designing nanoplatforms for durable systemic antitumor immunity.

Main Methods:

Synthesis of nanotechnology-based approaches for TDLN immune modulation.
Analysis of factors influencing lymphatic transport, retention, and release of immunomodulatory agents.
Examination of principles for achieving localized immune programming within lymph nodes.

Main Results:

Nanotechnology offers precise control over immunomodulatory agent delivery to TDLNs.
Understanding lymphatic access and intranodal behavior is critical for therapeutic efficacy.
Strategies can be designed to reprogram TDLNs into sites of immune activation.

Conclusions:

TDLNs represent actionable immunological control points for cancer immunotherapy.
Nanoplatforms can be rationally designed to leverage TDLNs for durable systemic antitumor immunity.
Overcoming challenges in sustained immune programming and balancing safety is key for clinical translation.